CKD
77
16
19
20
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
5.2%
4 terminated out of 77 trials
83.3%
-3.2% vs benchmark
12%
9 trials in Phase 3/4
20%
4 of 20 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 20 completed trials
Clinical Trials (77)
A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis
Suitability of Two Flavours of a High-energy, Low-protein Formula (Renalive® LP) in Chronic Kidney Disease Stage 3b-5 Outpatients in Taiwan
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
A Mechanistic Study on the Effect of HTD1801 Versus Placebo on Kidney Function in Patients With Type 2 Diabetes and Chronic Kidney Disease.
Effects of Dietary Phosphorus on Phosphorus and Calcium Whole-Body Balance and Kinetics in Moderate CKD
Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE)
Adia Med of Winter Park LLC Chronic Kidney Disease Research Study
Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)
Early Coronary Angiography in Advanced Chronic Kidney Disease With Acute Coronary Syndrome
Impact of Garlic on the Clinical Outcome in Chronic Hemodialysis Patients
Digital Care for Holistic Health in Older Adults With Diabetes and Multimorbidity
Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial
FAP-targeting PET/CT for Noninvasive Monitoring of Renal Fibrosis
The CPH-MBD Cohort Dietary Substudy - Comparison of Methods for Dietary Registrations
Impact of Intestinal Microbiota on Uremic Toxins Productions
Kidney-protective Intervention With Salt Substitute After Kidney Tumor Surgery
Effect of Roxadustat on Heart Failure Patients With Anaemia and Moderate-to-Severe Chronic Kidney Disease
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Hyperlipoproteinemia A as a Marker of Cardiovascular Risk in Patients With Stage 4 Chronic Kidney Disease
Pregnancy and Contraception Education in Chronic Kidney Disease (PACE-CKD)